Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in High-Risk Prostate Cancer
NCT04894188Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Pathologic Complete Response or Minimal Residual Disease Rate at 100 weeks. Started Jan 2022; status: recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04894188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894188.